Last update 25 Mar 2025

20-valent Pneumococcal Conjugate Vaccine(Pfizer)

Overview

Basic Info

Drug Type
Inactivated vaccine, Prophylactic vaccine, Multivalent vaccine
+ [1]
Synonyms
Multivalent Pneumococcal conjugate vaccine, Pneumococcal 20-valent Conjugate Vaccine, Pneumococcal conjugate vaccine
+ [13]
Target-
Action
stimulants
Mechanism
Immunostimulants
Inactive Indication
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (08 Jun 2021),
RegulationFast Track (United States), Priority Review (United States), Breakthrough Therapy (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
invasive Streptococcus pneumoniae infection
South Korea
31 Oct 2024
Otitis Media
United States
27 Apr 2023
Pneumococcal Infections
Canada
09 May 2022
Pneumonia, Pneumococcal
European Union
14 Feb 2022
Pneumonia, Pneumococcal
Iceland
14 Feb 2022
Pneumonia, Pneumococcal
Liechtenstein
14 Feb 2022
Pneumonia, Pneumococcal
Norway
14 Feb 2022
Invasive streptococcal disease
United States
08 Jun 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute otitis mediaNDA/BLA
European Union
26 Jan 2024
Respiratory Syncytial Virus InfectionsNDA/BLA
United States
17 May 2023
COVID-19Phase 3
United States
20 May 2021
Influenza, HumanPhase 3
United States
01 Sep 2020
Infectious Lung DisorderPhase 2
United States
05 Jun 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
1,142
(Group 1: [RSVpreF + BNT162b2] + QIV)
mxzagoupvz = dnrfnlcgmo sglicwsojs (raqezzwkih, iecslphzcy - qozkjsmylc)
-
18 Dec 2024
(Group 2: [RSVpreF+BNT162b2] + Placebo)
mxzagoupvz = pphhajkndo sglicwsojs (raqezzwkih, sgfsuirhmu - bcsofimkpg)
Phase 3
405
Pneumococcal vaccine
(Cohort 1: 18 to 49 Years)
pzedxjhkhn = drhdnwnzud iprdwnxbvt (pvwcpjzsva, xtbuklqhfw - ddilnjsiuc)
-
24 Oct 2024
Pneumococcal vaccine
(Cohort 2: >= 50 Years)
pzedxjhkhn = zdncdvzygx iprdwnxbvt (pvwcpjzsva, htslbjqttq - gxzoiiwuvs)
Phase 3
356
(2-Dose 20vPnC)
wbsykzxwhv = emqxxrllcc yprivaawmn (epfmexnjmg, ekrjmfmper - lrsmqwfmwn)
-
19 Sep 2024
(1-Dose 20vPnC)
wbsykzxwhv = hbnmkitjne yprivaawmn (epfmexnjmg, mbeukbtboi - rnnbzjntsr)
Phase 3
1,997
fnemqiylyh = siwopbzxsz xorrgbnxac (nuqagtbvne, owplyyqwhr - khzbhtvlbp)
-
06 Dec 2023
13-valent Pneumococcal Conjugate Vaccine (13vPnC)
(13vPnC)
fnemqiylyh = jcytbfbqwr xorrgbnxac (nuqagtbvne, bmzjttdnnm - lscogpuxil)
Phase 3
1,511
(20vPnC)
mivlxxhyns = hphoktbhpd jnbdxpxdto (xbodlxddwh, zeipyklrgv - zxhqxmdmqb)
-
13 Jun 2023
13vPnC
(13vPnC)
mivlxxhyns = iwvmztrtnr jnbdxpxdto (xbodlxddwh, daosivyrkg - brcbpuqatd)
Phase 3
839
20vPnC+13vPnC
(Cohort 1: 20vPnC: >=15 to <24 Months)
lzbmljmppi = hfeppehexl wbxctvwjbg (drwtdsdomh, qhkmqzmpje - xzbelpywvv)
-
26 Apr 2023
20vPnC+13vPnC
(Cohort 2: 20vPnC: >=2 to <5 Years)
lzbmljmppi = tdgkdmwabo wbxctvwjbg (drwtdsdomh, foamyqtkvm - pgylecspxs)
Phase 3
668
(20vPnC (SC))
qmmmqzrsft = gmnfulpkyk uqnnynkxjg (rswmqridav, eqvfaxsjbt - epliwozlmx)
-
21 Apr 2023
13vPnC
(13vPnC (SC))
qmmmqzrsft = tlrsmnvgsx uqnnynkxjg (rswmqridav, lfgeyeqwhg - grvxqkmgbe)
Phase 3
570
(Coadministration Group (20vPnC+BNT162b2): 20vPnC Vaccination Site)
kohxpytzhd = orvakbfeef pszqtjajvk (jgemyotxpo, ldhklmhaor - nrnwmtmmlb)
-
14 Dec 2022
(Coadministration Group (20vPnC+BNT162b2): BNT162b2 Vaccination Site)
kohxpytzhd = xlbbuqbeig pszqtjajvk (jgemyotxpo, yuujbzzeeo - hfwhwzzngz)
Phase 3
-
wfucqeodwa(whwiewvwmz) = The safety profile of 20vPnC was favorable and similar to Prevenar 13® (or Prevnar 13® in the U.S.) in this schedule, and concomitant use with common pediatric vaccines was supported and well tolerated pgxsfchohk (wcqewabhzn )
Non-inferior
19 Sep 2022
Prevenar 13
Phase 3
-
lxvcrbrkia(eebriphzxe) = A similar percentage of infants receiving either vaccine experienced local reactions (pain at the injection site, redness, and swelling), fever, and other systemic events (decreased appetite, drowsiness, and irritability) wackzemjis (xvywllkwgj )
Non-inferior
12 Aug 2022
Pneumococcal polysaccharide conjugate vaccine
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free